Soluble Interleukin-2 Receptor: A Potential Marker for Monitoring Disease Activity in IgG4-Related Disease
Table 1
Characteristics of patients with IgG4-RD.
Sex
Age
Disease manifestation of IgG4-RD
IgG4 before treatment
sIL-2R before treatment
Treatment/comments
1
M
53
Orbit and lymph nodes
17.7
3695
Rx: prednisone
2
M
36
Salivary gland
3.18
3441
Rx: initially prednisone and Aza, later RTX
3
M
42
Lymph nodes and kidney
3.0
12,400
Rx: prednisone and RTX, now CellCept
4
M
60
Orbit and lymph nodes
5.22
3700
Rx: prednisone and MTX
5
F
46
Orbit
2.76
3400
Rx: now infliximab
6
M
61
Orbit, lymph node, and prostate
13.48
5800
sIL-2R initially measured under low-dose prednisone but active disease. Now prednisone and MTX
7
M
57
Orbit, lymph node, and prostate and pancreas
13.40
5151
Rx: prednisone
8
M
63
Orbit, pancreas, ENT, and prostate
1.65
5700
Rx: prednisone
9
M
17
Lung, lymph nodes, and brain
10.30
3900
Rx: prednisone and RTX
10
M
53
Mesenteric manifestation
25.25
5900
Rx: prednisone and RTX
11
M
32
Pericardial and pleural manifestation
5.40
3500
Rx: prednisone
12
M
39
Orbit
1.65
8135
Rx: prednisone and Aza
13
M
29
Lymph node (Kimura disease)
1.17
3800
Patient declined treatment
14
M
55
Hypophysis and ENT
1.57
3100
Rx: prednisone
15
M
48
Mesenteric manifestation
3.01
14,027
Patient did not show up for follow-up/treatment
16
F
52
Orbit
0.61
2859
Surgical resection periorbital mass, no systemic treatment
17
M
61
Biliary tract and ENT
5.55
5300
Rx: prednisone
18
M
79
Lymph node
42.8
9000
Only lymph node manifestation, no systemic treatment
19
F
39
Salivary gland
3.97
3374
Rx: prednisone
20
M
74
Orbit and lymph node
8.82
6135
Rx: dexamethasone
21
F
52
Orbit and lymph node
3.27
2639
Rx: prednisone
22
M
74
Orbit and ENT
3.30
7977
Status after ocular surgery, currently no systemic treatment
23
F
61
Orbit and ENT
0.36
4182
Rx: prednisone
24
M
65
Retroperitoneal fibrosis
3.44
7100
Rx: prednisone
25
M
53
Orbit and ENT
1.45
4105
Rx: prednisone, MTX, and now RTX
26
F
59
Skin
1.18
10,800
Rx: prednisone and Plaquenil
Characteristics of patients with IgG4-RD, including serum IgG4 and serum sIL-2R before treatment. P = patient; Rx = treatment; MTX = methotrexate; Aza = azathioprine; RTX = rituximab, NA = not applicable; NM = not measured. Normal range of serum IgG4 is 0.08–1.40 g/l, and normal range of serum sIL-2R is below 2500 pg/ml.